Centauri Therapeutics secures £6M Series A extension to advance antimicrobial immunotherapy candidate
Centauri Therapeutics, a UK-based immunotherapy company headquartered in Alderley Park, has raised £6 million in a Series A extension led by the AMR Action Fund, bringing the total Series A financing to £30 million.

The best Articles in our Network